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Summary
Elevated levels of tumor necrosis factor (TNFa) are implicated in the development of insulin resistance, but the mechanisms
mediating these chronic effects are not completely understood. We demonstrate that TNFa signaling through TNF receptor
(TNFR) 1 suppresses AMPK activity via transcriptional upregulation of protein phosphatase 2C (PP2C). This in turn reduces
ACC phosphorylation, suppressing fatty-acid oxidation, increasing intramuscular diacylglycerol accumulation, and causing
insulin resistance in skeletal muscle, effects observed both in vitro and in vivo. Importantly even at pathologically elevated
levels of TNFa observed in obesity, the suppressive effects of TNFa on AMPK signaling are reversed in mice null for both
TNFR1 and 2 or following treatment with a TNFa neutralizing antibody. Our data demonstrate that AMPK is an important
TNFa signaling target and is a contributing factor to the suppression of fatty-acid oxidation and the development of lipid-
induced insulin resistance in obesity.Introduction
Obesity and type 2 diabetes are associated with a chronic in-
flammatory response that is characterized by abnormal cytokine
production and systemic insulin resistance (Wellen and Hotami-
sligil, 2005). It is becoming increasingly apparent that increased
lipid metabolites contribute to insulin resistance in skeletal mus-
cle (reviewed in Shulman, 2000). Recent work has demonstrated
that obesity and excess lipid accumulation within skeletal mus-
cle could trigger the activation of a serine/threonine kinase
cascade involving activation of protein kinase C (PKC) (Li et al.,
2004; Yu et al., 2002), IK kinase-b (IKK-b) (Arkan et al., 2005;
Yuan et al., 2001), and c-jun terminal amino kinase (JNK) (Hiro-
sumi et al., 2002). Of the proinflammatory cytokines, tumor
necrosis factor-a (TNFa) has been implicated in the pathogene-
sis of insulin resistance because it is elevated in the circulation
(Zinman et al., 1999), skeletal muscle (Saghizadeh et al., 1996),
and adipose tissue (Hotamisligil et al., 1995) of patients with
type 2 diabetes. TNFa expression is correlated with reduced
insulin-stimulated glucose disposal (Kern et al., 2001; Saghiza-
deh et al., 1996; Zinman et al., 1999), and a recent study has
demonstrated that an acute infusion inhibits insulin-stimulated
glucose disposal (Plomgaard et al., 2005). The link between in-
flammatory cytokines and insulin action in obesity and type 2
diabetes was first recognized by the discovery of adipose tissue
TNFa overexpression in obesity (Hotamisligil et al., 1993, 1994a,
1994b, 1995, 1996) and its impact on systemic insulin sensitivity
(Uysal et al., 1997). These studies have clearly shown that TNFa
causes metabolic dysregulation at multiple sites including al-CELL METABOLISM 4, 465–474, DECEMBER 2006 ª2006 ELSEVIER INtered lipid homeostasis and insulin signaling (Wellen and
Hotamisligil, 2005). However, the precise molecular signals
underlying TNFa-induced metabolic dysregulation are still
largely unknown.
AMP-activated protein kinase (AMPK) is pivotal in the regula-
tion of skeletal muscle fatty-acid metabolism (Steinberg et al.,
2006). AMPK activation results in increasing rates of skeletal
muscle fatty-acid oxidation by phosphorylating acetyl-CoA car-
boxylase (ACC), leading to reduced malonyl-CoA and increased
long-chain fatty acyl CoA flux into the mitochondria via carnitine
palmitoyl transferase-1 (Ruderman et al., 1999). The regulation
of AMPK is complex involving allosteric control by an increase
in the cellular AMP:ATP ratio (Kemp et al., 2003) and covalent
regulation through phosphorylation of Thr172 within the a cata-
lytic subunit by the upstream kinase LKB1 (Hawley et al., 2003;
Woods et al., 2003) and dephosphorylation by protein phospha-
tase 2C (PP2C) (Davies et al., 1995). AMPK is activated in skel-
etal muscle by hormones including leptin (Minokoshi et al.,
2002), adiponectin (Yamauchi et al., 2002), interleukin-6 (Carey
et al., 2006; Kelly et al., 2004), and ciliary neurotrophic factor
(Watt et al., 2006), while AMPK phosphorylation is suppressed
by resistin (Satoh et al., 2004). Defective skeletal muscle fatty-
acid metabolism in obesity involves suppressed rates of fatty-
acid oxidation (Gaster et al., 2004; Hulver et al., 2003; Kelley
and Simoneau, 1994) effects that may be related to reduced
skeletal muscle AMPK activity (Bandyopadhyay et al., 2006).
As TNFa is elevated in obesity and insulin resistance we tested
the hypothesis that suppressed rates of fatty-acid oxidation are
mediated via TNFa-induced inhibition of AMPK signaling.C. DOI 10.1016/j.cmet.2006.11.005 465
A R T I C L EResults and discussion
TNFa inhibits AMPK signaling via PP2C
To investigatewhether TNFaalteredAMPKsignaling, initial stud-
ies were conducted in cultured L6 muscle cells. TNFa reduced
AMPK activity after 8 hr of treatment, an effect that was main-
tained for 16 hr but was not significant at earlier time points
(Figure 1A). This effect was observed following 16 hr at concen-
trations of 10 and 100 ng/ml (Figure 1B). TNFa treatment (10 ng/
ml) for 16 hr suppressed basal and AICAR (5-aminoimidazole-
4-carboxamide) stimulated AMPK Thr172 phosphorylation and
ACCb phosphorylation (Figures 1C and 1D, respectively).
AMPK and ACC protein expression were unaltered (Figures 1C
and 1D).
LKB1 is the principal upstream kinase of AMPK in skeletal
muscle (Sakamoto et al., 2004). Consistent with previous stud-
ies, which have demonstrated that LKB1 is constitutively active
(Hawley et al., 2003; Woods et al., 2003), TNFa treatment for
16 hr did not alter LKB1 activity in L6myotubes (data not shown).
The covalent regulation of AMPK is also regulated by the activity
of PP2C (Davies et al., 1995). Consistent with the time course of
changes in AMPK activity, PP2C (also known as Ppm1a) mRNA
(Figure 1E) and PP2C protein expression (Figure 1F) were ele-
vated after 16 hr of TNFa treatment. These data indicated that in-
creasedPP2C levelsmay account for the reducedAMPKactivity
andphosphorylation observed following TNFa treatment. To test
this hypothesis directly we attempted to inhibit PP2C transcrip-
tion using short interfering RNA (siRNA) in L6 myoblasts. We
utilized low titers of PP2C siRNA which tended to modestly re-
duce basal PP2C expression (225%, p= 0.061, Figure 1G) but
importantly prevented TNFa-mediated regulation. This experi-
mental set-upwas critical so that the impact of PP2C expression
on AMPK activity could be examined without increasing basal
phosphorylation of AMPK (Figure 1H), hence avoiding complica-
tions of elevated AMPK in PP2C siRNA-treatedmyotubes. In this
paradigm, TNFa treatment for 16 hr increased PP2C expression
in Con siRNA but not PP2C siRNAmyotubes (Figure 1G). Impor-
tantly, AMPK phosphorylation was maintained in PP2C siRNA-
treated cells following TNFa treatment (Figure 1H).
Since AMPK is an important regulator of fatty-acid oxidation
we next examined whether the suppressive effects of TNFa on
AMPK activity altered ACC phosphorylation and fatty-acid
oxidation. In preliminary experiments TNFa suppressed ACC
phosphorylation and fatty-acid oxidation (227% and 217%,
p < 0.05, respectively). We therefore examined whether the
maintenance of AMPK signaling through inhibition of PP2C
transcription using siRNA as described above or a constitutively
active AMPK (a1T172D) adenovirus (Ad-CA) (Woods et al., 2000)
would reverse these downstream events. TNFa treatment sup-
pressedACCphosphorylation and fatty-acid oxidation in control
siRNA-treated cells, but this effect was reversed following PP2C
siRNA (Figures 2A and 2B). Similarly, in mock-infected cells (Ad
null), TNFa treatment reduced ACC phosphorylation (Figure 2A)
and palmitate oxidation (Figure 2B), but Ad-CA prevented the
suppressive effects of TNFa on ACC phosphorylation and
palmitate oxidation.
PP2C siRNA reverses TNFa-induced insulin resistance
TNFa-induced insulin resistance involves the inhibition of in-
sulin signaling by JNK (Hirosumi et al., 2002) and IkKb/NFkB
(Arkan et al., 2005; Cai et al., 2005). To determine whether the466Figure 1. TNF reduces AMPK activity in cultured skeletal muscle via protein
phosphatase 2C
A) TNFa reduced AMPK activity after 8 hr of treatment, an effect that was
maintained for 16 hr. B) Reduced AMPK activity was observed following 16 hr at
concentrations as low as 10 ng/ml. TNFa treatment (10 ng/ml) for 16 hr suppressed
basal and AICAR-stimulated (C) AMPK pThr172 and (D) ACC pS218. Consistent
with the time course of changes in AMPK activity, PP2C mRNA (E) and PP2C
protein (F) were elevated following 16 hr of TNFa treatment. Short interfering
RNA directed toward PP2C (PP2C siRNA) inhibited increases in PP2C protein
expression (G) and the suppression of AMPK pT172 (H) by TNFa. Values are
means 6 SEM (n = 6–12 for 2–3 separate experiments). ap < 0.05 versus time 0,
bp < 0.05 versus vehicle for that treatment, cp < 0.05 versus AICAR.CELL METABOLISM : DECEMBER 2006
TNFa suppresses skeletal muscle AMPKFigure 2. PP2C siRNA or a constitutively active
AMPK reverses TNFa effects on fatty-acid oxidation
and glucose uptake
TNFa suppressed (A) ACC pS218 and (B) palmitate
oxidation effects that were reversed in cells treated
with PP2C siRNA or infected with Ad-CA. (C) For
2-deoxyglucose uptake experiments cells were
treated with vehicle (PBS) or insulin (50 nM) for
20 min following treatment with or without TNFa for
16 hr. (D) For insulin signaling experiments cells
were treated with or without TNFa for 16 hr followed
by vehicle (PBS) or insulin (50 nM) for 5 min. Data are
presented as changes relative to insulin. Values are
means 6 SEM (n = 6–8 for 2 separate experiments).
ap < 0.05 versus vehicle. bp < 0.05 versus insulin from
the same condition.suppressive effects of TNFa onAMPK signaling also contributed
to the development of insulin resistance 2-DG uptakewas deter-
mined in L6 myotubes treated with PP2C siRNA or CA-AMPK
adenovirus as described above. Insulin increased glucose
uptake by w50% in both Con and PP2C siRNA-L6 myotubes.
As anticipated, a 16 hr treatment with TNFa partially suppressed
insulin-stimulated glucose uptake, but this effect was reversed
in PP2C siRNA-treated cells (Figure 2C). In Ad null infected cells
insulin increased glucose uptake by w25%. Reduced insulin-
stimulated glucose uptake relative to siRNA-treated cells ap-
peared tobedueprimarily toahigher rateofbasal glucoseuptake.
TNFa modestly inhibited glucose uptake in Ad null treated cells
but Ad-CA-infected cells were protected from TNFa-induced
suppression of insulin-stimulated glucose uptake (Figure 2C).
To examine the potential mechanism(s) by which PP2C siRNA
or Ad-CA may rescue TNFa-induced insulin resistance, we ex-
amined proximal and distal aspects of the insulin signaling path-
way including tyrosine phosphorylation of IRS1, p85 subunit of
PI3-kinase IRS1 association, and Akt phosphorylation. In this
experiment we compared insulin relative to TNFa plus insulin,
and because there were no significant differences in insulinCELL METABOLISM : DECEMBER 2006stimulation relative to basal controls between treatments (i.e.,
Con siRNA, PP2C siRNA, Ad null or Ad-CA) insulin conditions
were standardized across all groups. TNFa treatment sup-
pressed all aspects of insulin signaling in Con siRNA-treated
cells, an effect that was also observed in Ad null infected cells
with the exception of pAkt/Akt, which was not suppressed
following TNFa treatment (Figure 2D). Consistent with improved
2-DG uptake, cells treatedwith PP2C siRNA or Ad-CA displayed
improved insulin signaling following TNFa treatment relative to
TNFa-treated Con siRNA and Ad null myotubes (Figure 2D).
The mechanism by which PP2C siRNA or Ad-CA rescues
TNFa-induced insulin resistance is not clear but may involve
AMPK directly inhibiting JNK or NFkB, as has been demon-
strated in cultured endothelial cells (Cacicedo et al., 2004).
TNFa infusion inhibits AMPK signaling
To investigate if the effects of TNFa treatment on AMPK signal-
ing, fatty-acid oxidation, and insulin sensitivity observed in
cultured skeletal muscle also occurred in vivo, wild-type (WT)
or mice that lack the TNFR1 (p55) receptor (TNFR2/2) were
treated for 24 hr with TNFa at a dose previously demonstrated467
A R T I C L Eto induce skeletal muscle insulin resistance (Miles et al., 1997;
Ruan et al., 2002). TNFa treatment did not alter body mass or
food intake in WT controls or TNFR2/2 littermates (data not
shown). InWTbut notTNFR2/2miceTNFa suppressedAMPKa1
and a2 activities (Figure 3A). Reduced AMPK activity was due to
reduced AMPK-Thr172 phosphorylation (Figure 3A) as protein
expression was unaltered following TNFa treatment (Figure
3A). Consistent with our observations in cultured skeletal
muscle, reductions in AMPKThr172 phosphorylation were asso-
ciated with elevated PP2CmRNA (Figure 3B) and PP2C activity
(Figure 3C) following TNFa treatment in WT but not TNFR2/2
mice. The activities of protein phosphatase 2A (PP2A) and pro-
tein phosphatase 1 (PP1) were unaltered as was LKB1 expres-
sion and activity (Table S1). Reduced AMPK activity following
TNFa treatment was associated with reduced phosphorylation
of ACCb in WT but not TNFR2/2mice (Figure 3D).
AMPK activity is also regulated allosterically by alterations in
the AMP:ATP ratio via the AMPKg subunit (Adams et al., 2004;
Cheung et al., 2000). We found that TNFa did not alter skeletal
muscle nucleotide levels (Table S1). Reduced activation of
AMPK by AICAR (Aschenbach et al., 2002; Wojtaszewski et al.,
2002) or contraction (Derave et al., 2000; Kawanaka et al.,
2000) have been correlated with high glycogen levels, although
the mechanisms by which this occurs are not clear. Glycogen
levels tended to be reduced following TNF treatment in WT and
TNFR2/2mice (Table S1, p = 0.11).
TNFa infusion increases skeletal muscle lipid
Consistent with reduced AMPK and ACCb phosphorylation,
TNFa suppressed fatty-acid oxidation (Figure 3E). Suppressed
AMPK activity and fatty-acid oxidation in WT mice treated with
TNFa was associated with increased triacylglycerol (TAG) and
diacylglycerol (DAG) (Figure 3F) accumulation in skeletalmuscle.
TNFa had no effect on ceramide accumulation inWTorTNFR2/2
mice (WT: saline 546 10, TNF 556 6; TNFR2/2: saline 536 10,
TNF 63 6 5 nmol/g dm). These data demonstrate that TNFa
signaling through the p55/TNFR1 is critical for mediating the
effects of TNFa on AMPK signaling and fatty-acid oxidation.
Several studies have implicated elevated DAG in the develop-
ment of skeletal muscle insulin resistance by direct inhibition of
insulin signaling through the activation of the novel PKC isoforms
3 and q (Kim et al., 2004; Yu et al., 2002). We therefore sought to
examine whether the TNFa-mediated increases in DAG content
were associated with enhanced PKC activation. Consistent with
this hypothesis, TNFa treatment increased the expression of
membrane-associated/activated DAG-sensitive PKC isoforms
q and 3 in skeletal muscle of WT but not TNFR2/2 mice
(Figure 4A). PKC a/b1/b2 were not different between groups or
treatments (data not shown). In separate experiments, we as-
sessed the effect of TNFa treatment on insulin sensitivity using
the hyperinsulinemic-euglycaemic clamp technique. Treatment
with TNFa in WT mice suppressed rates of whole-body glucose
disposal/Rd (Figure 4B), reduced 2-deoxyglucose uptake in the
red gastrocnemius (Figure 4C), red andwhite quadriceps, brown
adipose tissue, and diaphragm (Table S2), and tended to reduce
2-deoxyglucose uptake in heart and white adipose tissue (Table
S2). TNFa-induced insulin resistance in WT animals was asso-
ciated with reduced IRS1 tyrosine phosphorylation, reduced
association of IRS1 with the p85 catalytic subunit of PI3-K, and
reduced phosphorylation of Akt (Ser473) in WTmice (Figure 4D).
Skeletal muscle insulin sensitivity and insulin signaling were468conserved in TNFR2/2 mice (Figures 4B–4D). Taken together
these observations indicate that suppressed AMPK signaling
by TNFa may contribute to the development of TNFa-mediated
skeletal muscle insulin resistance in vivo. While we cannot elim-
inate the possibility that the effects of TNFa in vivo were second-
ary to reductions in leptin, adiponectin, or other cytokines that
signal via AMPK, our findings are consistent with the direct
Figure 3. TNF suppresses skeletal muscle AMPK signaling via PP2C in vivo
Wild-type (WT) and TNFR2/2mice were treated with vehicle or TNFa for 24 hr. (A)
AMPKa1 and a2 activities were measured from gastrocnemius muscle lysates in
immunocomplexes (representative Western blot of pT172AMPK relative to total
AMPKa1 and a2 expression above), (B) PP2C mRNA, (C) PP2C activity, (D)
ACCb phosphorylation relative total ACC expression (representative Western
blot [above] and quantification [below]). (E) Fatty-acid oxidation in isolated soleus
muscle. (F) Mixed gastrocnemius triacylglycerol and diacylglycerol lipid. Values
are means 6 SEM (n = 6–8). ap < 0.05 versus saline. bp < 0.05 versus wild-type.CELL METABOLISM : DECEMBER 2006
TNFa suppresses skeletal muscle AMPKFigure 4. TNF suppression of AMPK signaling is
associated with insulin resistance in vivo
Wild-type (WT) and TNFR2/2mice were treated with
vehicle or TNFa for 24 hr and fasted overnight before
euglycemic-hyperinsulinemic clamping studies. (A)
Protein kinase C (PKC) expression was measured
in cytosolic and membrane fractions isolated from
60 mg of insulin-stimulated gastrocnemius muscle
collected following the clamp and immunoblotted
using phosphospecific antibodies to PKC 3 and q.
Values are means 6 SEM (n = 5) and are expressed
as a ratio of membrane versus cytosolic densitome-
try scanning units. TNFa treatment induced periph-
eral insulin resistance as indicated by (B) suppressed
whole-body glucose rate of disappearance (Rd) and
(C) 2-deoxyglucose uptake into gastrocnemius
muscle following TNFa treatment in WT but not
TNFR2/2 animals. (D) To examine components of
the insulin signaling pathway, insulin-stimulated gas-
trocnemius muscle were collected following the
euglycemic-hyperinsulinemic clamp and homoge-
nized. Wild-type and TNFR2/2 mice that were
treated with vehicle or TNFa for 24 hr and fasted
overnight but not clamped were used as basal con-
trols. IRS1 and associated p85 PI3 kinase were
immunoprecipitated from muscle homogenates
(1 mg protein) using anti-IRS1 antibody bound pro-
tein A beads, then immunoblotted for tyrosine phos-
phorylation and p85 PI3 kinase. Muscle homoge-
nates were also immunoblotted for phosphorylated
and total Akt and p85. Values are means 6 SEM
(n = 5) corrected for total IRS1, p85, and Akt relative
to basal unstimulated muscle for that group.
ap < 0.05 versus saline.effects of TNFa on PP2C expression, AMPK signaling, and fatty-
acid oxidation in skeletal muscle cells.
Inhibition of TNFa signaling in obesity rescues AMPK
signaling and impaired lipid metabolism
Several reports have demonstrated reduced skeletal muscle
AMPK activity with rodent obesity (Barnes et al., 2002; Yu
et al., 2004). A recent study has suggested that in cardiac mus-
cle PP2Cmay mediate this effect, as elevated PP2C expression
was associated with reduced AMPK phosphorylation in ob/ob
mice and Obese Zucker rats, although mechanisms mediating
this association were not determined (Wang and Unger, 2005).
These findings together with those of our own raise the possibil-
ity that TNFa neutralization may prevent the defective AMPK
signaling observed in obesity. To test this hypothesis, untreated
male lean mice (body mass, 21 6 0.3 g, n = 6) were compared
with obese ob/ob littermates that were treated with either
a control (body mass, 48.2 6 2.8 g, n = 6) or TNFa (body
mass, 46.8 6 2.2 g, n = 6) neutralizing monoclonal antibody
for 48 hr. TNFa neutralization did not restore extensor digitorium
longus (EDL) insulin-stimulated glucose uptake (Table S3), indi-
cating that skeletal muscle insulin resistance was not reversedCELL METABOLISM : DECEMBER 2006following 48 hr of treatment. As anticipated control ob/ob mice
had significantly lower AMPKa2 activity (Figure 5A) and phos-
phorylation (Figure 5B) than lean controls, an effect that was
associatedwithmodestly elevatedPP2Cexpression (Figure 5C).
TNF neutralization in ob/ob mice restored AMPKa2 activity and
phosphorylation and reduced PP2C expression to that of lean
controls. Obesemice displayed reduced ACCb phosphorylation
(229%, p = 0.062, Figure 5D) and fatty-acid oxidation (p = 0.02,
Figure 5E) and increased DAG (p = 0.01, Figure 5F), defects that
were not observed following TNF neutralization. These data
demonstrate that elevated levels of TNFa are an important
contributing factor to the suppressed rates of fatty-acid oxida-
tion and the development of lipid-induced insulin resistance in
obesity.
Interestingly, while 48 hr of TNFa neutralization restored
AMPK activity and phosphorylation to that of lean controls,
this treatment resulted in no noticeable improvement in skeletal
muscle insulin sensitivity of ob/ob mice. Obesity, insulin resis-
tance, and the accumulation of intramuscular lipid correlate
with mitochondrial dysfunction (Petersen et al., 2004), and ob/
ob mice have reduced mitochondrial density (Tanaka et al.,
2003). It seems reasonable that these defects may be due to469
A R T I C L Ereduced AMPK activity, as AMPK is important for mitochondrial
biogenesis (Zong et al., 2002), suggesting that amore prolonged
neutralization period may have been effective in reversing these
defects. Supporting this idea are findings that chronic treatment
of ob/ob mice with rosiglitazone, which is an AMPK activator
(Fryer et al., 2002) and suppressor of TNFa production (Jiang
et al., 1998), reverses defects in mitochondrial density in
adipose tissue (Wilson-Fritch et al., 2004). Our data are also in
agreement with findings in cardiac muscle in which reduced
AMPK phosphorylation in ob/ob mice was associated with
elevated PP2C expression effects that were reversedwith trogli-
Figure 5. TNF neutralization in ob/ob mice reverses defects in AMPK signaling
and fatty-acid oxidation
Untreated lean mice and obese ob/ob mice were treated with either a control or
TNF-neutralizing monoclonal antibody for 48 hr. (A) AMPKa1 and a2 activities,
(B) AMPKa2 phosphorylation, (C) PP2C protein expression, (D) ACCb phosphory-
lation, (E) soleus palmitate oxidation, and (F) mixed gastrocnemius DAG. Values
are means6 SEM (n = 5–6) ap < 0.05 versus lean. bp < 0.05 versus ob/ob-control.470tazone (Wang and Unger, 2005). Taken together these data indi-
cate that a principal mechanism by which PPARg agonists
reverse defects in fatty-acid metabolism and therefore insulin
sensitivity may be through the suppression of TNFa production.
Uysal et al. (Uysal et al., 1997) demonstrated that ob/obmice
that lack both the p55 and p75 isoforms of the TNFR (ob/ob
TNFR2/2) display enhanced insulin sensitivity relative to ob/ob
control mice despite similar degrees of obesity. We therefore
examined whether improved insulin sensitivity in ob/ob
TNFR2/2 mice involved enhanced AMPK signaling. AMPKa1
and a2 activities were higher (+49 and 76%, p = 0.026 and p =
0.027 respectively) in ob/ob TNFR2/2 relative ob/ob controls
(Figure 6A). Increased AMPK activity was associated with re-
duced PP2C expression (Figure 6B) and elevated ACCb phos-
phorylation (Figure 6C), suggesting that increases in fatty-acid
oxidation may contribute to the enhanced insulin sensitivity ob-
served in ob/ob TNFR2/2 mice.
Conclusions
Studies in rodents and humans have established a causative
role for TNFa in the development of skeletal muscle insulin resis-
tance; however the signaling mechanisms by which chronically
elevated levels of TNFa inhibit insulin signaling have not been
fully elucidated. Defective skeletal muscle fatty-acid metabo-
lism in obesity involves suppressed rates of fatty-acid oxidation
(Gaster et al., 2004; Hulver et al., 2003; Kelley and Simoneau,
1994), effects which may be related to reduced skeletal muscle
AMPK activity (Bandyopadhyay et al., 2006; Barnes et al., 2002;
Yu et al., 2004). In the present study we demonstrate a pathway
mediated by TNFa involving the upregulation of PP2C and
subsequent suppression of AMPK phosphorylation/activity and
fatty-acid oxidation (Figure 7). Importantly, we demonstrate that
even at physiologically elevated levels of TNFa, as observed in
ob/ob mice, the effects of TNFa on PP2C and AMPK activity
persist. As such these data demonstrate that TNFa suppression
of AMPK signaling contributes to defective fatty-acid metabo-
lism in obesity and is an important contributing factor to the
development of insulin resistance.
Experimental procedures
Animals
All experimental protocols were approved by St. Vincent’s Hospital’s Animal
Ethics Committee. TNFR1 null mice were derived from 129/OlaHsd (E14 ES
cells) and backcrossed to C57BL/6 for two generations and then back-
crossed into NOD/Lt for seven generations before being intercrossed to
generate homozygous mice. At backcross seven, the NOD genes around
the TNFR1 locus were mapped and NOD DNA was found at D6Mit135
(51.4cM) and D6Mit14 (63.4cM). The TNFR1 locus is at about 57 cM. Micro
osmotic pumps (Model 1003D, Alzet, Palo Alto, California) were implanted
into both WT and TNFR1 null littermates as previously described (Steinberg
et al., 2002), and TNF (1 mg/kg/day) or saline was infused for 24 hr. This con-
centration of TNFawas selected as it has previously demonstrated to induce
skeletal muscle insulin resistance (Ruan et al., 2002) and increase plasma
levels tow630 ng/ml (Miles et al., 1997). Following the prescribed treatment
fatty-acid oxidation was determined in soleus muscle as previously de-
scribed (Steinberg and Dyck, 2000) and gastrocnemius were removed and
snap frozen for analysis of AMPK activity, phosphorylation of ACCb, protein
phosphatase activity and expression, and muscle metabolites and sub-
strates (see below). In separate experiments to assess insulin sensitivity via
hyper-insulinemic-euglycaemic clamps, animals were fasted overnight (see
below). For TNF antibody treatment experiments male ob/ob (n = 6) mice
(Monash Mouseworks, Clayton, Victoria Australia) 10–12 weeks of age
were injected at 0 and 24 hr with 500 mg of control or TNF-neutralizingCELL METABOLISM : DECEMBER 2006
TNFa suppresses skeletal muscle AMPKantibody (clone XT3) (Korner et al., 2000) and tissues collected for determina-
tion of fatty-acid metabolism and AMPK signaling as described above. Lean
littermates (+/ob) served as controls. Obese TNFR-deficient mice (ob/ob
TNFR2/2) were generated as previously described (Uysal et al., 1997).
Cell culture transfection, infection, and lysis
L6 myoblasts were maintained on 10 cm plates in a-MEM with 10% fetal
bovine serum (FBS) culture media at 37C in 5%CO2 humidified air. Differen-
tiation was induced by switching to medium containing 2% FBS when the
myoblasts werew90% confluent. Experimental treatments were started af-
ter 7 days, by which time nearly all of the myoblasts had fused to form myo-
tubes. Myotubes were serum starved for 16 hr in a-MEM + 0.1% FBS and
treated with or without TNFa (R&D systems) at the indicated concentrations
and times, which have been used previously to induce insulin resistance in
skeletal muscle myotubes (De Alvaro et al., 2004). In separate experiments
cells were treated as described above followed by incubation for 30 min
with AICAR (2 mM, 5-aminoimidazole-4-carboxamide, Toronto, Research
Chemicals Inc. Toronto, Canada). For experiments involving adenovirus in-
fection, L6myotubeswere infectedwith adenovirus containing control vector
(Ad null) or the constitutively active AMPK mutant (Ad-CA) as previously
described (Woods et al., 2000). Adenoviral expression levels of both Ad
null and Ad-CA infected cells were determined by visual examination of green
fluorescent protein under ultraviolet light. Seventy-two hours post-infection
w85%of all myotubes were infected in both Ad null and Ad-CA infected cells
(data not shown). Cells were then serum starved and treated with vehicle or
TNFa (10 ng/ml) for 16 hr before cells were harvested or treated with vehicle
or insulin for insulin signaling or glucose uptake experiments. For PP2C
Figure 6. Enhanced whole-body insulin sensitivity of ob/ob TNFR2/2 mice is as-
sociated with increased AMPK signaling and reduced PP2C expression
Skeletal muscle from obese ob/ob TNFR2/2 mice and ob/ob controls. (A) Repre-
sentative pThr172 phosphorylation relative AMPK (above) and AMPKa1 and a2
activities (below), (B) PP2C protein expression, and (C) ACCb phosphorylation.
Values are means 6 SEM (n = 8). ap < 0.05 versus ob/ob.CELL METABOLISM : DECEMBER 2006siRNA experiments, myoblasts were grown to w90% confluence. Media
were then changed to serum and antibiotic-free low-glucose DMEM and
Con (scramble) and PP2C oligonucleotides were transfected as described
(Yoshizaki et al., 2004). After 24 hr, media were changed to aMEM with 1%
FBS containing vehicle or TNFa for 16 hr before cells were harvested or
treated with insulin for insulin signaling or glucose uptake experiments.
Analytical methods
AMPKa1 and a2 activities and ACCb phosphorylation
Isoform-specific AMPK activities and phosphorylation were measured in
muscle and cell lysates using rabbit polyclonal AMPK antibodies for immuno-
precipitation and immunoblotting as previously described (Chen et al., 1999).
LKB1 activity
LKB1 assays were performed following immunoprecipitation with LKB1
antibody (Upstate) on the beads using a two-step reaction with full-length,
bacterially expressed human AMPK (a1,b1,g1), as previously described
(Chen et al., 2005).
Protein phosphatase assays
Protein phosphatase activity in muscle homogenates was determined by
measuring the generation of g 32Pi from 32P-labeled casein prepared using
amodification of the procedure described previously (Mackintosh andMoor-
head, 1999). Casein was phosphorylated by protein kinase A incubated with
375 mM [g -32P] ATP (2500 cpm/pmole) in 50 mM Hepes (pH 7.5), 10 mM
MgCl2, 5% glycerol, 1 mM DTT buffer at 20
C for 16 hr. The reaction was
terminated by the addition of 100 mM NaF, 10 mM Na4P2O7 (pH 7). The
free g 32P was removed by G-25 chromatography using PD-10 columns
(Amersham Biosciences, United Kingdom). Approximately 0.1 mole Pi/mole
casein was achieved yielding approximately 40 mM 32P-labeled casein.
Muscle samples (w100 mg) were homogenized in 50 mM Hepes, pH 7.5,
2 mM EDTA, 1 mM DTT, 1% NP40, 10 mg/ml aprotinin, 10 mg/ml soyabean
trypsin inhibitor, 1 mM PMSF (7 ml/ mg) then cleared by centrifugation at
14,000 rpm for 10 min. To detect phosphatase activities the muscle extracts
Figure 7. Proposed schematic outlining mechanism by which elevated TNFamay
induce insulin resistance471
A R T I C L E(10 ml3 50 mg/ml) were incubatedwith 5 nM okadaic acid (OA) to inhibit PP2A
exclusively, 100 nMOA to inhibit both PP1 and PP2A, or 20mMMgCl2 (6 100
nMOA) to activate PP2C (and inhibit PP1 and PP2A), with 5 mM 32P-casein in
50 mM Hepes, pH 7.5, 1 mM DTT, 0.1% Triton X-100 for 15 min at 30C in
25 ml. Twenty percent TCA (100 ml) was added to stop the reaction and
precipitate casein. The free 32P in the supernatant fraction was measured
by liquid scintillation counting.
Total RNA was isolated from skeletal muscle samples using Trizol reagent
(Invitrogen) according to the manufacturer’s protocol. For each sample 3 mg
RNAwas reverse transcribed using the SuperScript II first strand synthesis kit
(Invitrogen) and oligo dT primers, in a final volume of 20 ml. Samples were di-
luted 1:100 in water and 1 ml used for quantitation. Real-time quantitative RT-
PCR was performed on an ABI Prism 5700 Sequence Detection system
(Perkin-Elmer Applied Biosystems, Australia), as previously reported (Stein-
berg et al., 2004). Reactions were performed in triplicate and the results were
normalized against the RPL32 ‘‘housekeeping’’ gene. Relative gene expres-
sion was determined using the comparative Ct method. Amplification of
PP2C mRNA was performed using forward (TGTCAATGGCTCTCTGGCTG
TATC) and reverse (ACACTCATGTTGTCTCGACTTCCC) oligonucleotides
that amplify all three PP2C transcript variants (variant 1 NM_021003, variant
2 NM_177951, and variant 3 NM_177952). The use of primer pairs specific for
each of the transcript variants revealed negligible expression of transcript
variants 2 and 3 (data not shown). PP2C protein expression was determined
via immunoblot of cell and muscle lysates from 100 mg of protein using
a PP2Cab antibody (Abcam, Cambridge, United Kingdom).
Measurement of glycogen, nucleotides, and lipid species
Muscle glycogen, nucleotides, and lipids were analyzed as previously
described (Watt et al., 2006).
Euglycemic-hyperinsulinemic clamps
A primed (2 min, 3 mCi.min21) continuous infusion (0.15 mCi.min21) of [6-3H]-
glucose was administered during basal and euglycaemic-hyperinsulinaemic
clamp experiments to measure whole-body glucose turnover, as we have
previously described (Jamieson et al., 2005) with minor modifications. Blood
glucose concentration was maintained at basal levels by the infusion of a 5%
glucose solution. Blood samples were collected during steady-state condi-
tions at 90, 100, and 110 min. Following the collection of blood samples for
measurement of whole-body glucose turnover, a bolus of 2-[1-14C]-deoxy-
glucose (10 mCi) was injected intravenously and blood samples were col-
lected at 2, 5, 10, 15, 30, and 45 min. Immediately following the collection
of the last blood sample at 45 min, animals were sacrificed by a lethal over-
dose of pentobarbitone sodium and tissues including heart, diaphragm,
quadriceps (red and white), soleus, gastrocnemius (red and white), brown
adipose, andwhite adipose tissuewere rapidly removed, frozen in liquid nitro-
gen, and stored at 270C for subsequent analysis. The time course of
2-[1-14C]-deoxyglucose disappearance from plasma and the levels of phos-
phorylated 2-deoxyglucose accumulation in individual tissues were deter-
mined as previously described (Kraegen et al., 1985).
Fatty-acid oxidation and glucose uptake/insulin signaling
experiments in L6 myotubes
Fatty-acid oxidation in L6myotubes was determined as previously described
(Chen et al., 2005). For 2-deoxyglucose assays, L6myotubeswere incubated
in the presence or absence of insulin (50 nM) for 30 min followed by incuba-
tion with 10 mM 2-deoxyglucose (Sigma) and 1 mCi/ml 2-[1-14C]-2-deoxyglu-
cose (Amersham, Life Sciences) for 20 min as described (Watt et al., 2006).
For insulin signaling L6 myotubes were treated with vehicle or insulin
(50 nM) for 5 min and harvested in ice-cold lysis buffer. Clarified lysates
were immunoprecipiated with an IRS1 antibody (Santa Cruz) prebound to
protein-A agarose beads and immunoblotted with phosphotyrosine (4G10,
Upstate) and PI3 Kinase p85 (Upstate) antibodies. Phosphorylated Akt
(Ser473), total Akt, and p85 (Cell Signaling) were measured via immunoblot
from 100 mg of protein as described (Carey et al., 2006).
PKC translocation and IRS1/Akt signaling
Insulin-stimulated gastrocnemius skeletal muscle extracts and cell lysates
(1 mg) were immunoprecipitated using antibodies and procedures as previ-
ously described (Jamieson et al., 2005). PKC expression was measured in
cytosolic and membrane fractions isolated from 60 mg of gastrocnemius472muscle as described (Michell et al., 2001) and immunoblotted using phos-
phospecific antibodies (Cell Signaling).
Statistical analysis
Results are expressed as the mean 6 SEM. Data were analyzed for differ-
ences by one-way analysis of variance with specific differences located
with a Student Newman-Keuls post-hoc test or a Student’s t test for unpaired
samples where appropriate. p < 0.05 was considered to be statistically
significant.
Supplemental data
Supplemental data include three tables and can be found with this article
online at http://www.cellmetabolism.org/cgi/content/full/4/6/465/DC1/.
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